BACKGROUND: Plasma human immunodeficiency virus type 1 (HIV-1) RNA suppression <50 copies/mL is regarded as the optimal outcome of highly active antiretroviral therapy (HAART). Current viral load (VL) assays show increased sensitivity, but the significance of RNA detection <50 copies/mL is unclear. METHODS: This study investigated the virologic outcomes of 1247 patients with VL <50 copies/mL at an arbitrary time point during HAART (= T0), according to whether the actual, unreported (T0)VL was 40-49 copies/mL, RNA detected <40 copies/mL (RNA(+)), or RNA not detected (RNA(-)), as measured by the Abbott Real Time assay. Predictors of rebound >50 and >400 copies/mL over 12 months following T0 were analyzed with Cox proportional hazards models incorporating the (T0)VL and demographic and clinical data. RESULTS: Rebound rates >50 copies/mL were 34.2% for (T0)VL 40-49 copies/mL, 11.3% for RNA(+), and 4.0% for RNA(-); rebound rates >400 copies/mL were 13.0%, 3.8%, and 1.2%, respectively. The adjusted hazard ratios for rebound >50 copies/mL were 4.67 (95% confidence interval, 2.91-7.47; P < .0001) and 1.97 (1.25-3.11; P < .0001) with (T0)VL 40-49 copies/mL and RNA(+), respectively, relative to RNA(-), and 6.91 (2.90-16.47; P < .0001) and 2.88 (1.24-6.69; P < .0001), respectively, for rebound >400 copies/mL. The association was independent of adherence levels. CONCLUSIONS: In treated patients monitored by RealTime, a VL of 40-49 copies/mL and, to a lesser extent, RNA detection <40 copies/mL predict rebound >50 and >400 copies/mL independently of other recognized determinants. The goal of HAART may need to be revised to a lower cutoff than 50 copies/mL.
BACKGROUND: Plasma human immunodeficiency virus type 1 (HIV-1) RNA suppression <50 copies/mL is regarded as the optimal outcome of highly active antiretroviral therapy (HAART). Current viral load (VL) assays show increased sensitivity, but the significance of RNA detection <50 copies/mL is unclear. METHODS: This study investigated the virologic outcomes of 1247 patients with VL <50 copies/mL at an arbitrary time point during HAART (= T0), according to whether the actual, unreported (T0)VL was 40-49 copies/mL, RNA detected <40 copies/mL (RNA(+)), or RNA not detected (RNA(-)), as measured by the Abbott Real Time assay. Predictors of rebound >50 and >400 copies/mL over 12 months following T0 were analyzed with Cox proportional hazards models incorporating the (T0)VL and demographic and clinical data. RESULTS: Rebound rates >50 copies/mL were 34.2% for (T0)VL 40-49 copies/mL, 11.3% for RNA(+), and 4.0% for RNA(-); rebound rates >400 copies/mL were 13.0%, 3.8%, and 1.2%, respectively. The adjusted hazard ratios for rebound >50 copies/mL were 4.67 (95% confidence interval, 2.91-7.47; P < .0001) and 1.97 (1.25-3.11; P < .0001) with (T0)VL 40-49 copies/mL and RNA(+), respectively, relative to RNA(-), and 6.91 (2.90-16.47; P < .0001) and 2.88 (1.24-6.69; P < .0001), respectively, for rebound >400 copies/mL. The association was independent of adherence levels. CONCLUSIONS: In treated patients monitored by RealTime, a VL of 40-49 copies/mL and, to a lesser extent, RNA detection <40 copies/mL predict rebound >50 and >400 copies/mL independently of other recognized determinants. The goal of HAART may need to be revised to a lower cutoff than 50 copies/mL.
Authors: Victor G Kramer; Susan M Schader; Maureen Oliveira; Susan P Colby-Germinario; Daniel A Donahue; Diane N Singhroy; Randy Tressler; Richard D Sloan; Mark A Wainberg Journal: Antimicrob Agents Chemother Date: 2012-05-21 Impact factor: 5.191
Authors: Sarah B Joseph; Laura P Kincer; Natalie M Bowman; Chris Evans; Michael J Vinikoor; Christopher K Lippincott; Magnus Gisslén; Serena Spudich; Prema Menezes; Kevin Robertson; Nancie Archin; Angela Kashuba; Joseph J Eron; Richard W Price; Ronald Swanstrom Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Christina M Lalama; Cheryl Jennings; Victoria A Johnson; Robert W Coombs; John E McKinnon; James W Bremer; Bryan R Cobb; Gavin A Cloherty; John W Mellors; Heather J Ribaudo Journal: J Clin Microbiol Date: 2015-06-10 Impact factor: 5.948
Authors: Katherine M Rich; Javier Valencia Huamaní; Sara N Kiani; Robinson Cabello; Paul Elish; Jorge Florez Arce; Lia N Pizzicato; Jaime Soria; Jeffrey A Wickersham; Jorge Sanchez; Frederick L Altice Journal: AIDS Care Date: 2018-05-30
Authors: Silvia Baroncelli; Maria F Pirillo; Enrica Tamburrini; Giovanni Guaraldi; Carmela Pinnetti; Anna Degli Antoni; Clementina M Galluzzo; Chiara Stentarelli; Roberta Amici; Marco Floridia Journal: AIDS Res Hum Retroviruses Date: 2015-04-08 Impact factor: 2.205
Authors: J Saison; T Ferry; J Demaret; D Maucort Boulch; F Venet; T Perpoint; F Ader; V Icard; C Chidiac; G Monneret Journal: Clin Exp Immunol Date: 2014-06 Impact factor: 4.330